These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 756132)

  • 1. [Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma].
    Ludwig H; Schneider K; Pietschmann H
    Acta Med Austriaca; 1978; 5(4-5):164-6. PubMed ID: 756132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New aspects in the clinical course determination and therapy in multiple myeloma].
    Ludwig H; Pietschmann H
    Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis and therapy of multiple myeloma].
    Sonntag RW
    Schweiz Med Wochenschr; 1978 Aug; 108(32):1247-51. PubMed ID: 675217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma: a therapeutic enigma.
    Hoogstraten B
    Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and treatment of generalized plasmacytoma (multiple myeloma)].
    Andreeva NE; Antipova LG
    Ter Arkh; 1977; 49(8):76-85. PubMed ID: 929397
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings: Treatment of multiple myeloma by a quadruple chemotherapy regime.
    Azam L; Delamore IW
    Br J Haematol; 1974 Jun; 27(2):362. PubMed ID: 4843684
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of plasmacytoma].
    Gassel WD; Sodomann CP
    Ther Ggw; 1980 Sep; 119(9):980-1005. PubMed ID: 7466705
    [No Abstract]   [Full Text] [Related]  

  • 8. A new basis for treatment of multiple myeloma.
    Salmon SE; Durie BG; Hamburger AW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Protracted pulse" chemotherapy for refractory myeloma: a preliminary report.
    Manoharan A
    Eur J Haematol; 1990 Nov; 45(5):274-5. PubMed ID: 2261956
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
    Cantore M; Smerieri F; Bucalossi A; Leoncini L
    Recenti Prog Med; 1991 Nov; 82(11):598-602. PubMed ID: 1763233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone].
    Sezaki T; Ishii H; Osada T; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1982 Jun; 23(6):847-53. PubMed ID: 7176091
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on chemotherapy for multiple myeloma. Part II: Prognostic factors of treatment with prednisolone and sequential melphalan and ifosfamide: MIP therapy].
    Sezaki T; Ishii H; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):433-9. PubMed ID: 6887543
    [No Abstract]   [Full Text] [Related]  

  • 16. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K; Anger G
    Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
    Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
    Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor proliferation and chemotherapy in immunosuppressed mice.
    Ghanta VK; Shrestha K; Durant JR; Hiramoto RN
    Cancer Res; 1983 Mar; 43(3):1097-100. PubMed ID: 6825081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal onset of multiple myeloma].
    Goranov S; Atanasov K; Dimitrakov D; Vakhrilov V; Diukmedzhiev I
    Vutr Boles; 1988; 27(2):74-9. PubMed ID: 3414104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.